Skip to main content

Table 1 Baseline patient characteristics of HFpEF progressor and non-progressor cohorts

From: Biomarker profiling for risk of future heart failure (HFpEF) development

Median [IQR] or N (%) Total study cohort HFpEF progressor HFpEF Non progressor p-value
N 90 30 60  
Age 75.0 [69.1:78.2] 76.0 [69.8:78.1] 74.3 [68.8:78.2] 0.4828
Male 42 (46.7%) 14 (46.7%) 28 (46.7%)  > 0.99
BMI 29.0 [25.0:34.5] 33.0 [25.2:36.8] 27.0 [25.0:30.0] 0.0710
SBP 137.5 [124.2:151.0] 128.0 [111.2:144.5] 140.5 [130.0:151.5] 0.1181
DBP 78.0 [70.2:84.0] 73.5 [65.2:82.5] 80.0 [75.8:86.0] 0.0197
HDL 1.2 [1.0:1.5] 1.2 [1.0:1.5] 1.2 [1.0:1.5] 0.7979
Triglycerides 1.6 [1.1:2.0] 1.6 [1.1:2.0] 1.5 [1.1:2.1] 0.8742
RAAS 69 (76.7%) 24 (80.0%) 45 (75.0%) 0.7920
AA 0 (0.0%) 0 (0.0%) 0 (0.0%) -
ARB 38 (42.2%) 14 (46.7%) 24 (40.0%) 0.7060
ACEI 35 (38.9%) 13 (43.3%) 22 (36.7%) 0.7020
Diuretic 40 (44.4%) 18 (60.0%) 22 (36.7%) 0.0610
BB 48 (53.3%) 19 (63.3%) 29 (48.3%) 0.2620
CCB 45 (50.0%) 17 (56.7%) 28 (46.7%) 0.5020
Anti-platelet 59 (65.6%) 22 (73.3%) 37 (61.7%) 0.3880
EF 67.0 [62.0:72.8] 66.0 [62.0:72.0] 68.0 [62.0:73.0] 0.4690
Lateral e’ 7.1 [5.8:8.8] 7.8 [6.2:10.5] 6.5 [5.5:8.2] 0.0298
Peak E 73.0 [62.0:86.0] 79.5 [69.8:95.0] 69.0 [58.0:81.0] 0.0016
E / lat. e’ 10.4 [8.0:13.7] 10.4 [8.2:12.7] 10.6 [7.9:13.7] 0.9477
LAVI 33.0 [28.1:40.4] 41.5 [29.4:48.2] 31.5 [28.0:36.1] 0.0029
LVMI 102.4 [83.4:114.7] 105.9 [102.2:126.0] 97.4 [79.9:111.8] 0.0284
LVDD* 26 (34.7%) 12 (46.2%) 14 (28.6%) 0.2050
  1. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high density lipoprotein cholesterol, RAAS renin angiotensin aldosterone system modifying therapy, AA aldosterone antagonists, ARB aldosterone receptor blocker, ACEI angiotensin converting enzyme inhibitor, Loop loop diuretics, BB beta blocker, CCB calcium channel blocker, EF ejection fraction, LAVI left atrial volume index, LVMI left ventricular mass index, LVDD left ventricular diastolic dysfunction. *LAVI > 34 and e’ < 10